Outcomes of Transcatheter Tricuspid Valve-in-Valve Implantation in Patients With Ebstein Anomaly.

Taggart, Nathaniel W; Cabalka, Allison K; Eicken, Andreas; Aboulhosn, Jamil A; Thomson, John D R; Whisenant, Brian; Bocks, Martin L; Schubert, Stephan; Jones, Thomas K; Asnes, Jeremy D; Fagan, Thomas E; Meadows, Jeffery; Hoyer, Mark; Martin, Mary H; Ing, Frank F; Turner, Daniel R; Latib, Azeem; Tzifa, Aphrodite; Windecker, Stephan; Goldstein, Bryan H; ... (2018). Outcomes of Transcatheter Tricuspid Valve-in-Valve Implantation in Patients With Ebstein Anomaly. American journal of cardiology, 121(2), pp. 262-268. Elsevier 10.1016/j.amjcard.2017.10.017

Text 1-s2.0-S0002914917316272-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (373kB)

We sought to describe the acute results and short- to medium-term durability of transcatheter tricuspid valve-in-valve (TVIV) implantation within surgical bioprostheses among patients with Ebstein anomaly (EA). Cases were identified from a voluntary, multicenter, international registry of 29 institutions that perform TVIV. Demographic, clinical, procedural, and follow-up data were analyzed. Eighty-one patients with EA underwent TVIV from 2008 to 2016. Thirty-four patients (42%) were New York Heart Association (NYHA) class 3/4 at time of TVIV. The most common indication for TVIV was the presence of moderate or severe tricuspid regurgitation (40%). Most patients received a Melody valve (64%). TVIV was ultimately successful in all patients, and there was no procedural mortality. Four patients (5%) developed acute valve thrombosis, 4 patients (5%) developed endocarditis, and 9 patients (11%) developed valve dysfunction not related to thrombosis or endocarditis. Eight patients (10%) underwent reintervention (2 transcatheter, 6 surgical) due to thrombosis (3), endocarditis (2), other valve dysfunction (2), and patient-prosthesis mismatch without valve dysfunction (1). Among 69 patients who were alive without reintervention at latest follow-up, 96% of those with NYHA status reported were class 1/2, a significant improvement from baseline (62% NYHA class 1/2, p <0.001). In conclusion, transcatheter TVIV offers a low-risk, minimally invasive alternative to surgical tricuspid valve re-replacement in patients with EA and a failing tricuspid valve bioprosthesis.

Interest & Impact

Downloads

1 since deposited on 16 Apr 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item